Mammoth Biosciences
Mammoth Biosciences is a biotechnology company based in South San Francisco, California developing diagnostic tests using CRISPR-Cas12a. The company was founded in 2017[1] by Jennifer Doudna, Janice Chen, Trevor Martin, and Lucas Harrington of the University of California, Berkeley.[2] Mammoth signed agreements in December 2019 and January 2020 with Horizon Discovery to combine Mammoth's intellectual property in CRISPR with Horizon's expertise in Chinese hamster ovary cells.[3] Also in 2020, both Mammoth Biosciences and Sherlock Biosciences from the Broad Institute used their similar CRISPR technologies to develop tests for COVID-19.[4] The technology, which is owned under the trademark of DETECTR BOOST, has been contracted to be manufactured by Merck & Co.[5]
See also
References
- ^ "Mammoth Biosciences". Craft.co. Archived from the original on 2021-05-27. Retrieved 2021-05-27.
- ^ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 422–423. ISBN 978-1-9821-1585-2.
- ^ "Horizon Discovery, Mammoth Biosciences Sign Second CRISPR Tools Development Agreement". Genomeweb. 2020-01-13. Retrieved 2021-05-27.
- ^ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 427–433. ISBN 978-1-9821-1585-2.
- ^ Mcardle, Matthew (May 17, 2021), Increasing SARS-CoV-2 testing capacity with CRISPR-based rapid testing, SelectScience, retrieved September 9, 2021
{{citation}}: CS1 maint: date and year (link)
 | This corporation or company article is a stub. You can help Wikipedia by expanding it. |